A number of pharmaceutical agents are currently under evaluation for the treatment of dry AMD using strategies such as reduction RPE and photoreceptor loss, neuroprotection,
visual cycle modulators, suppression of inflammation, prevention of oxidative damage, and choroidal perfusion enhancers.
Acucela is focused on developing oral therapeutics based on its proprietary
visual cycle modulation technology, and its lead investigational drug candidate, emixustat hydrochloride, is being developed to address proliferative diabetic retinopathy.